Synonym
KME 4; KME-4; KME4
IUPAC/Chemical Name
alpha-(3,5-di-tert-Butyl-4-hydroxybenzylidene)gamma-butyrolactone
InChi Key
DFPYHQJPGCODSB-LCYFTJDESA-N
InChi Code
InChI=1S/C19H26O3/c1-18(2,3)14-10-12(9-13-7-8-22-17(13)21)11-15(16(14)20)19(4,5)6/h9-11,20H,7-8H2,1-6H3/b13-9-
SMILES Code
OC1=C(C(C)(C)C)C=C(C=C1C(C)(C)C)/C=C(CCO2)\C2=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
302.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hidaka T, Takeo K, Hosoe K, Katsumi I, Yamashita T, Watanabe K. Inhibition of polymorphonuclear leukocyte 5-lipoxygenase and platelet cyclooxygenase by alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), a new anti-inflammatory drug. Jpn J Pharmacol. 1985 Jul;38(3):267-72. PubMed PMID: 3932730.
2: Hidaka T, Hosoe K, Ariki Y, Takeo K, Yamashita T, Katsumi I, Kondo H, Yamashita K, Watanabe K. Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase. Jpn J Pharmacol. 1984 Sep;36(1):77-85. PubMed PMID: 6438380.
3: Hidaka T, Hosoe K, Katsumi I, Yamashita T, Watanabe K. The effect of alpha-(3,5-di-t-butyl-4-hydroxybenzylidene)-gamma-butyrolactone (KME-4), a new anti-inflammatory drug, on leucocyte migration in rat carrageenan pleurisy. J Pharm Pharmacol. 1986 Mar;38(3):244-7. PubMed PMID: 2871169.
4: Hidaka T, Hosoe K, Yamashita T, Watanabe K. Effect of alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolactone (KME-4), a new anti-inflammatory drug, on the established adjuvant arthritis in rats. Jpn J Pharmacol. 1986 Oct;42(2):181-7. PubMed PMID: 3795622.
5: Hidaka T, Hosoe K, Yamashita T, Watanabe K, Hiramatsu Y, Fujimura H. Analgesic and anti-inflammatory activities in rats of alpha-(3,5-di-t-butyl-4-hydroxybenzylidene)-gamma-butyrolactone (KME-4), and its intestinal damage. J Pharm Pharmacol. 1986 Oct;38(10):748-53. PubMed PMID: 2878995.
6: Katsumi I, Kondo H, Yamashita K, Hidaka T, Hosoe K, Yamashita T, Watanabe K. Studies on styrene derivatives. I. Synthesis and antiinflammatory activities of alpha-benzylidene-gamma-butyrolactone derivatives. Chem Pharm Bull (Tokyo). 1986 Jan;34(1):121-9. PubMed PMID: 3698124.
